Regeneron announced Eylea injection recommended for approval in EU Regeneron announced that EYLEA Injection has been recommended for approval by the European Committee for Medicinal Products for Human Use for the treatment of visual impairment due to diabetic macular edema. The decision of the European Commission is expected in the second half of 2014. The European Union submission is based on positive data from the Phase 3 VIVID-DME and VISTA-DME studies.
News For REGN From The Last 14 Days
Check below for free stories on REGN the last two weeks.
Regeneron expected to receive priority review at Piper Jaffray Piper Jaffray expects Regeneron (REGN) and Sanofi (SNY) will receive priority review for alirocumab via the priority review voucher recently acquired from BioMarin (BMRN). Piper says potential approval of the drug is likely by mid-2015 and it reiterates an Overweight rating on Regeneron with a $382 price target.
Regeneron price target raised to $436 from $389 at Leerink Leerink raised its price target for Regeneron shares to $436 after its survey of 100 physicians indicated potential blockbuster status for the company's PCSK9-inhibitor Alirocumab. The firm reiterates an Outperform rating on the stock.